Revised American Thyroid Association Guidelines for Managing Medullary Thyroid Carcinoma
GAVRETO® (pralsetinib) has been withdrawn for RET-mutant medullary thyroid cancer (MTC) in the US
Free Videos with Experts
After the Diagnosis: MTC Memoirs — A Book for Anyone Touched by Cancer
Medullary Thyroid Carcinoma (MTC) Registry Consortium Invites Patient Participation
2010
2007
Medullary Thyroid Cancer Slide Presentation with Audio, at the 2007 Annual Meeting of The Endocrine Society. Speakers are Douglas Ball, MD, Robert Gagel, MD, Martin Schlumberger, MD, and Samuel Wells, MD. Access free of charge through this link: http://www.sessions2view.com/endo_library/Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels. A.L. Giraudet, M. Schlumberger, MD, et al. Journal of Clinical Endocrinology and Metabolism, Vol. 92, No. 11 4185-4190, August 2007Evidence-Based Approach to the Management of Sporadic Medullary Thyroid Carcinoma. J. Moley, MD, E.A. Fialkowski, MD, World Journal of Surgery; Vol. 31(5):946-56, May 2007Medullary Thyroid Cancer: Therapeutic Targets and Molecular Markers. D. W. Ball, MD, Current Opinion in Oncology, Vol. 19 No. 1:18-23, January 2007
2006
Current Approaches to Medullary Thyroid Carcinoma, Sporadic and Familial. E.A. Fialkowski, MD, and J.F. Moley, MD. Journal of Surgical Oncology, Vol. 94, No. 8:737-47.